Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214–221.
••A complete history on protein PEGylation.
- Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72:217–224.
- Monfardini C, Schiavon O, Caliceti P, et al. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjugate Chem. 1995;6:62–69.
- Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today. 2005;10:1451–1458.
- Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27:1186–1190.
- Food and Drug Adminstration Drug Approval Package [Internet]. Cimzia (Certolixumab Pegol) injection. UCB, Inc. Application No. 125160 [cited 2015 Nov 6]. 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm.
- Sundy JS, Barag HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to coventional treatment. JAMA. 2001;306:711–720.
•Phase III study in patients treated with Krystexxa demonstrating that the development of antibodies to PEGylated drug, believed to be directed to the PEG portion of the molecule, can decrease treatment efficacy.
- Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
- Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;10:103–111.
•Retrospective study investigating PEG antibodies in patients treated with Oncaspar that demonstrated the presence of PEG antibodies enhanced the drug’s clearance rate.
- Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19:11–20.
- Webster R, Elliott V, Park BK. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications. Switzerland: Birkhauser Verlag; 2009. p. 127–146.